Esperion Therapeutics, Inc. (ESPR) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Esperion Therapeutics, Inc.'s filing signal turned positive.

Esperion Therapeutics is a commercial-stage biopharmaceutical company focused on developing and commercializing oral, once-daily, non-statin medicines for patients with cardiovascular disease and elevated LDL-C. Its lead products, NEXLETOL(R) (bempedoic acid) and NEXLIZET(R) (bempedoic acid and ezetimibe), are indicated to reduce cardiovascular risk and lower LDL-C. The company secured FDA approval for these products in 2020, with expanded indications for cardiovascular risk reduction approved in March 2024. Esperion has established international partnerships with companies like Daiichi Sankyo Europe GmbH, Otsuka Pharmaceutical Co., Ltd., and Daiichi Sankyo Co. Ltd. to commercialize its products globally. The company's strategy includes executing its commercialization plan for existing products, advancing its preclinical pipeline of next-generation ACLY inhibitors, and broadening its portfolio through business development.

Esperion derives revenue from net product sales of NEXLETOL and NEXLIZET in the U.S., and from collaboration revenue, which includes milestone payments, sales of bulk tablets to partners, and royalty revenue from international commercialization efforts.